Richard L. Schilsky, MD, on Highlights of the 2016 ASCO Annual Meeting

2016 ASCO Annual Meeting

Richard L. Schilsky, MD, ASCO’s Chief Medical Officer, discusses the key presentations at this year’s conference.

Lisa A. Carey, MD, and Julie Gralow, MD: Top Breast Cancer Papers Presented at the 2016 ASCO Annual Meeting

Lisa A. Carey, MD, of the University of North Carolina, and Julie Gralow, MD, of the University of Washington, discuss the most important data presented this year on treating breast malignancies (Abstracts LBA1, 500, and 507).

Multiple Myeloma

Michele Cavo, MD, on Multiple Myeloma: Results From a European Myeloma Network Trial

Michele Cavo, MD, of the Seràgnoli Institute of Hematology, Bologna University School of Medicine, discusses results from this phase III study of upfront autologous stem cell transplantation vs novel agent-based therapy for multiple myeloma (Abstract 8000). To see the Italian version of this interview, please click here.

Solid Tumors

John D. Hainsworth, MD, on Advanced Solid Tumors: Results From the MyPathway Trial

John D. Hainsworth, MD, of the Sarah Cannon Research Institute, discusses early findings from this umbrella basket study on targeted treatment, outside of current drug indications, for different types of advanced solid tumors (Abstract LBA11511).

Multiple Myeloma

Michele Cavo, MD, on Multiple Myeloma: Results From a European Myeloma Network Trial (Italian Language Version)

Michele Cavo, MD, of the Seràgnoli Institute of Hematology, Bologna University School of Medicine, discusses in Italian results from this phase III study of upfront autologous stem cell transplantation vs novel agent-based therapy for multiple myeloma (Abstract 8000).

To see the English language version of this video, please click here.

Skin Cancer

Anthony J. Olszanski, RPh, MD, and Michael A. Davies, MD, PhD, on the COMBI-d Study on Cutaneous Melanoma

Anthony J. Olszanski, RPh, MD, of Fox Chase Cancer Center, and Michael A. Davies, MD, PhD, of the University of Texas MD Anderson Cancer Center, discuss this phase III study of dabrafenib plus trametinib vs dabrafenib monotherapy in patients with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma (Abstract 9502).

Aug

Today In Oncology

Richard L. Schilsky, MD, on Highlights of the 2016 ASCO Annual Meeting

Related Videos

Lisa A. Carey, MD, and Julie Gralow, MD: Top Breast Cancer Papers Presented at the 2016 ASCO Annual Meeting

Michele Cavo, MD, on Multiple Myeloma: Results From a European Myeloma Network Trial

John D. Hainsworth, MD, on Advanced Solid Tumors: Results From the MyPathway Trial

Michele Cavo, MD, on Multiple Myeloma: Results From a European Myeloma Network Trial (Italian Language Version)

Anthony J. Olszanski, RPh, MD, and Michael A. Davies, MD, PhD, on the COMBI-d Study on Cutaneous Melanoma

Adding Dendritic Cell Vaccination to Hepatocellular Carcinoma Therapy

Identifying CNS Tumors With Multianalyte Cerebrospinal Fluid Test

How to Adapt to the Era of AI and the Changing Interactions With Patients: Lessons From a Low-Resource Setting

Analysis Shows No Major Racial Differences in Somatic Mutations of Triple-Negative Breast Cancer

Survey Finds Discordance Between Treatment Preferences and Clinical Care for Advanced Cancer